Estabrook Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Estabrook Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-7	Closed	-$54	–	359
2018 Q2	$54	Hold	7	–	–	﹤0.01%	358
2018 Q1	$252	Hold	7	–	–	﹤0.01%	362
2017 Q4	$307	Hold	7	–	–	﹤0.01%	366
2017 Q3	$309	Hold	7	–	–	﹤0.01%	387
2017 Q2	$267	Hold	7	–	–	﹤0.01%	389
2017 Q1	$390	Hold	7	–	–	﹤0.01%	393
2016 Q4	$382	Hold	7	–	–	﹤0.01%	433
2016 Q3	$436	Hold	7	–	–	﹤0.01%	402
2016 Q2	$474	Hold	7	–	–	﹤0.01%	416
2016 Q1	$408	Hold	7	–	–	﹤0.01%	426
2015 Q4	$1.69K	Hold	7	–	–	﹤0.01%	417
2015 Q3	$1.14K	Hold	7	–	–	﹤0.01%	433
2015 Q2	$2.72K	Hold	7	–	–	﹤0.01%	404
2015 Q1	$3.01K	Hold	7	–	–	﹤0.01%	414
2014 Q4	$1.97K	Hold	7	–	–	﹤0.01%	427
2014 Q3	$1.4K	Hold	7	–	–	﹤0.01%	436
2014 Q2	$1.76K	Hold	7	–	–	﹤0.01%	435
2014 Q1	$1.91K	Hold	7	–	–	﹤0.01%	435
2013 Q4	$2.62K	Hold	7	–	–	﹤0.01%	427
2013 Q3	$3.83K	Hold	7	–	–	﹤0.01%	425
2013 Q2	$1.69K	Buy	+7	New	+$1.38K	﹤0.01%	442

Other funds holding CLDX

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Estabrook Capital Management's CLDX Position: Q3 2018 in Review

Estabrook Capital Management sold out of Celldex Therapeutics (CLDX) in Q3 2018, closing a stake of 7 shares — an estimated $54 sold.

Estabrook Capital Management first reported a position in CLDX in Q2 2013 and held it in 21 quarters. The position peaked at $3.83K in Q3 2013. 95 funds tracked by Wall St. Rank hold CLDX as of Q3 2018.

Estabrook Capital Management reported no remaining Celldex Therapeutics position as of Q3 2018 after selling out during the quarter.
Estabrook Capital Management sold 7 Celldex Therapeutics shares in Q3 2018, an estimated $54.
Estabrook Capital Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 21 quarters.
Estabrook Capital Management's Celldex Therapeutics position peaked at $3.83K in Q3 2013.
95 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2018.

Based on Estabrook Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.